Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Norman

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Expert Opinion on Therapeutic Patents|July 20, 2013
Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423)Peter Norman
Expert Opinion on Therapeutic Patents|July 3, 2015
Developments in inhaled combination therapies: patent activity 2013-2014Peter Norman
Drug News & Perspectives|April 5, 2003
Natural Products as a Source of New DrugsPeter Norman
Drug News & Perspectives|April 5, 2003
The Role of Bioinformatics in Identifying and Defining Potential Drug TargetsPeter Norman
Expert Opinion on Therapeutic Patents|February 11, 2010
Dual-acting beta2 agonists/muscarinic antagonistsPeter Norman
Pharmaceutical Patent Analyst|May 10, 2017
Humira<sup>®</sup>: recent developmentsPeter Norman
Current Opinion in Investigational Drugs (London, England : 2000)|April 27, 2007
Major developments in the endocrine and metabolic field between 2006 and 2007Peter Norman
Expert Opinion on Therapeutic Patents|January 19, 2012
Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: evaluation of WO20111411802Peter Norman
Expert Opinion on Therapeutic Patents|November 16, 2011
A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033Peter Norman
Expert Opinion on Therapeutic Patents|September 23, 2011
A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916Peter Norman
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Expert Opinion on Therapeutic Patents|July 20, 2013
Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423)Peter Norman
Expert Opinion on Therapeutic Patents|July 3, 2015
Developments in inhaled combination therapies: patent activity 2013-2014Peter Norman
Drug News & Perspectives|April 5, 2003
Natural Products as a Source of New DrugsPeter Norman
Drug News & Perspectives|April 5, 2003
The Role of Bioinformatics in Identifying and Defining Potential Drug TargetsPeter Norman
Expert Opinion on Therapeutic Patents|February 11, 2010
Dual-acting beta2 agonists/muscarinic antagonistsPeter Norman
Pharmaceutical Patent Analyst|May 10, 2017
Humira<sup>®</sup>: recent developmentsPeter Norman
Current Opinion in Investigational Drugs (London, England : 2000)|April 27, 2007
Major developments in the endocrine and metabolic field between 2006 and 2007Peter Norman
Expert Opinion on Therapeutic Patents|January 19, 2012
Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: evaluation of WO20111411802Peter Norman
Expert Opinion on Therapeutic Patents|November 16, 2011
A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033Peter Norman
Expert Opinion on Therapeutic Patents|September 23, 2011
A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916Peter Norman
Pageof 9